The U.S. Food and Drug Administration has approved Sogroya (somapacitan-beco), a once-weekly growth hormone injection, for children aged 2.5 years and older who experience growth failure due to Turner syndrome—a genetic disorder affecting roughly one in every 2,000 female births. The regulatory milestone, announced November 20, 2026, opens a new chapter for pediatric endocrinology by offering an alternative to daily injections for young patients and their families.
Turner syndrome, caused by a missing or incomplete X chromosome, commonly leads to short stature among other medical challenges. Growth hormone therapy has long been the mainstay treatment, but until now, U.S. patients have relied on daily injections. Sogroya, manufactured by Novo Nordisk, is now the first and only long-acting, once-weekly option approved for these children.
Evidence and Trial Results
The FDA’s decision was underpinned by the REAL8 Phase 3 clinical trial involving 105 children with Turner syndrome aged 2.5 to 10 years. The study compared weekly Sogroya injections (0.24 mg/kg) with standard daily somatropin injections (0.05 mg/kg). After 52 weeks, both groups showed substantial improvement in annualized height velocity—children on Sogroya grew an average of 8.9 cm per year, while those on somatropin grew 9.7 cm per year. The estimated difference of -0.8 cm per year (95% CI: -1.58; 0.07) fell within the trial’s non-inferiority margin, supporting that Sogroya’s effectiveness parallels that of the conventional daily treatment.
Secondary measures, including changes in height standard deviation scores, similarly favored the new therapy, though daily somatropin showed slightly greater improvement (0.86 vs. 0.77 for Sogroya).
Safety Considerations
Sogroya’s most common side effects during trial and in broader use include respiratory tract infections, ear and throat inflammation, fever, gastrointestinal disturbances, and local injection site reactions. FDA guidance recommends regular eye exams for children receiving Sogroya—papilledema should be excluded to guard against rare but serious intracranial hypertension. Doctors are also urged to monitor blood sugar, especially for children already at risk for diabetes.
Broader Impact and Next Steps
With this approval, Sogroya’s pediatric label expands beyond its earlier indication for idiopathic short stature, small-for-gestational age, and Noonan syndrome to now include Turner syndrome. Novo Nordisk’s product was also the first once-weekly treatment to be cleared for adult growth hormone deficiency in August 2020.
For children and families affected by Turner syndrome, the once-weekly schedule may mean less disruption from injections and potentially improved adherence. According to FDA records and Novo Nordisk’s statement, there are no significant unresolved issues or safety signals unique to this new indication, and no conflicting reports have emerged from the clinical community at this time.
The landmark approval marks another step toward modernizing chronic therapy for pediatric patients living with rare genetic conditions. Physicians will be watching closely as Sogroya enters pediatric endocrinology practices nationwide.